Related references
Note: Only part of the references are listed.Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study
David W. Dempster et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Effect of Teriparatide on Bone Formation in the Human Femoral Neck
Felicia Cosman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial
Benjamin Z. Leder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Involvement of WNT/β-catenin Signaling in the Treatment of Osteoporosis
Maurizio Rossini et al.
CALCIFIED TISSUE INTERNATIONAL (2013)
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
Joy N. Tsai et al.
LANCET (2013)
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin
Davide Gatti et al.
BONE (2012)
Sclerostin and DKK1 in Postmenopausal Osteoporosis Treated With Denosumab
Davide Gatti et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Effects of Intravenous Zoledronic Acid Plus Subcutaneous Teriparatide [rhPTH(1-34)] in Postmenopausal Osteoporosis
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
The Waning of Teriparatide Effect on Bone Formation Markers in Postmenopausal Osteoporosis Is Associated with Increasing Serum Levels of DKK1
Davide Gatti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway
Asiri R. Wijenayaka et al.
PLOS ONE (2011)
Vertebral fracture assessment using a semiquantitative technique
Harry K. Genant et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent
Felicia Cosman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk
Kaisa K. Ivaska et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate
Paul D. Miller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis
Steven Boonen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy
F. Cosman et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF
Ken-ichi Fujita et al.
MOLECULAR CANCER (2007)
Minireview:: Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton
Roland Baron et al.
ENDOCRINOLOGY (2007)
Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis
Tony M. Keaveny et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis
Yanfei L. Ma et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Wnt signalling in osteoblasts regulates expression of the receptor activator of NFκB ligand and inhibits osteoclastogenesis in vitro
GJ Spencer et al.
JOURNAL OF CELL SCIENCE (2006)
Daily and cyclic parathyroid hormone in women receiving alendronate
F Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation
DA Glass et al.
DEVELOPMENTAL CELL (2005)
Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate
B Ettinger et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis
JR Zanchetta et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Recombinant human parathyroid hormone (1-34) [Teriparatide] improves both cortical and cancellous bone structure
YB Jiang et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis:: A paired biopsy study
DW Dempster et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2001)
Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study
P Garnero et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
Share Paper
